It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lung emphysema and chronic bronchitis are the two most common causes of chronic obstructive pulmonary disease. Excess macrophage elastase MMP-12, which is predominantly secreted from alveolar macrophages, is known to mediate the development of lung injury and emphysema. Here, we discovered the endolysosomal cation channel mucolipin 3 (TRPML3) as a regulator of MMP-12 reuptake from broncho-alveolar fluid, driving in two independently generated Trpml3−/− mouse models enlarged lung injury, which is further exacerbated after elastase or tobacco smoke treatment. Mechanistically, using a Trpml3IRES-Cre/eR26-τGFP reporter mouse model, transcriptomics, and endolysosomal patch-clamp experiments, we show that in the lung TRPML3 is almost exclusively expressed in alveolar macrophages, where its loss leads to defects in early endosomal trafficking and endocytosis of MMP-12. Our findings suggest that TRPML3 represents a key regulator of MMP-12 clearance by alveolar macrophages and may serve as therapeutic target for emphysema and chronic obstructive pulmonary disease.
Excess macrophage elastase MMP-12 is a major driver of chronic obstructive pulmonary disease. Here the authors show that the endolysosomal ion channel TRPML3 is a regulator of the cellular reuptake of MMP-12, thus neutralizing harmful MMP-12 in the lung.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 Ludwig-Maximilians-University, Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 Ludwig-Maximilians-University, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); Institute for Neurophysiology, Hannover Medical School, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
3 Ludwig-Maximilians-University, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); National Taiwan University, Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241)
4 Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525)
5 Ludwig-Maximilians-University, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
6 Saarland University, Center for Molecular Signaling (PZMS), Experimental Pharmacology, Homburg, Germany (GRID:grid.11749.3a) (ISNI:0000 0001 2167 7588)
7 University Hospital Munich, Division of Clinical Pharmacology, Department of Medicine IV, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585)
8 Christian-Albrechts-University Kiel, Institute of Biochemistry, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
9 University Hospital Munich, Institute of Laboratory Medicine, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585)
10 Liège University, FARAH Mammalian Transgenics Platform, Liège, Belgium (GRID:grid.4861.b) (ISNI:0000 0001 0805 7253)
11 Northwestern University, Feinberg School of Medicine, Departments of Anesthesiology, Physiology and Neurology, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
12 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
13 University Hospital Munich, Division of Clinical Pharmacology, Department of Medicine IV, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585); German Center for Translational Cancer Research (DKTK), partner site Munich, Munich, Germany (GRID:grid.411095.8)
14 Ludwig-Maximilians-University, Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); Johannes-Keppler-University, Institute of Pharmacology, Linz, Australia (GRID:grid.5252.0)
15 Ludwig-Maximilians-University, Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X); German Center of Lung Research (DZL), Munich, Germany (GRID:grid.452624.3)
16 Institute for Neurophysiology, Hannover Medical School, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)